...
首页> 外文期刊>Open access Rheumatology: Research and Reviews >Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone
【24h】

Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone

机译:关节内注射在膝骨关节炎中的临床疗效:一项比较透明质酸和倍他米松的前瞻性随机研究

获取原文
           

摘要

Background: Osteoarthritis (OA) is the most common joint disease and leading cause of disability. Intra-articular (IA) administration of hyaluronic acid (HA) or corticosteroids (CS) have been previously studied, though using insufficient number of patients or short follow-up periods.Objective: We evaluate HA and CS in patients with knee OA in terms of clinical efficacy over 12 months.Methods: We used a prospective, randomized study with parallel groups. Randomized patients received IA injections of HA or betamethasone (BM). The primary outcomes were improvement in pain using Visual Analog Scale and function in the Western Ontario and McMaster University Osteoarthritis Index (Likert scale). Follow-up visits were scheduled at 3 months, 6 months, 9 months, and 12 months.Results: A total of 200 patients were included. Pain was significantly reduced in both groups at the first follow-ups. At 12 months, the mean pain reduction in the HA group was 33.6% (95% CI: 31.1–36.1) compared to 8.2% (95% CI: 5.2–11.1) in BM (P<0.0001). Function improvement was higher in HA through every visit, and mean improvement at 12 months was 47.5% (95% CI: 45.6–49.3) in HA patients vs 13.2% (95% CI: 11.4–14.9) in the BM group (P<0.0001). All patients from both groups achieved the Minimal Clinically Important Improvement (MCII) for both pain and function up to 6 months. At 9 months and 12 months, the MCII figures were higher in HA group with ≥80% compared to ≤10% in BM group (P<0.0001). Adverse reactions were rare and related to the administration procedure.Conclusion: Both treatments effectively controlled OA symptoms. BM showed higher short-term effectiveness, while HA showed better long-term effectiveness, maintaining clinical efficacy in a large number of patients 1 year after administration.
机译:背景:骨关节炎(OA)是最常见的关节疾病,也是致残的主要原因。尽管没有足够的患者数量或较短的随访时间,但先前已经研究过关节腔内(IA)透明质酸(HA)或皮质类固醇(CS)的给药。目的:我们从膝关节OA的角度评估HA和CS方法:我们对12个平行组进行了一项前瞻性随机研究。随机分组的患者接受IA注射HA或倍他米松(BM)。主要结果是使用视觉模拟量表和西安大略省麦克马斯特大学骨关节炎指数(Likert量表)的功能改善疼痛。随访时间分别为3个月,6个月,9个月和12个月。结果:总共包括200名患者。第一次随访时两组疼痛均明显减轻。在12个月时,HA组的平均疼痛减轻为33.6%(95%CI:31.1–36.1),而BM组为8.2%(95%CI:5.2-11.1)(P <0.0001)。每次访视时,HA的功能改善均较高,并且HA患者在12个月时的平均改善为47.5%(95%CI:45.6–49.3),而BM组为13.2%(95%CI:11.4-14.9)(P < 0.0001)。两组患者的疼痛和功能均达到了6个月的最小临床重要改善(MCII)。在9个月和12个月时,HA组的MCII值较高,≥80%,而BM组的MCII值≤10%(P <0.0001)。不良反应少见,且与给药过程有关。结论:两种治疗均能有效控制OA症状。 BM表现出较高的短期疗效,而HA表现出较好的长期功效,在给药后1年内对许多患者保持了临床疗效。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号